4507:TSEShionogi & Co., Ltd. Analysis
Data as of 2026-03-13 - not real-time
¥3,409.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Shionogi posted a 23.5% revenue surge, lifting nine‑month sales to ¥360.7 bn. Its gross margin of 84.5% and operating margin of 50% underline a highly profitable business model. At a trailing P/E of 16.9, the stock trades well below the industry average of 26.3, suggesting relative cheapness. However, the DCF‑derived fair value of ¥6,064 implies the current price of ¥3,409 is modestly overvalued by about 5‑6%. The company’s balance sheet is robust, with ¥215.6 bn cash offsetting ¥22.8 bn debt, yielding a net‑cash position. A dividend yield of 1.94% and a payout ratio near 33% indicate sustainable income for shareholders.
Technically, the price sits above the 50‑day SMA (¥3,254) but below the 20‑day SMA (¥3,520), reflecting short‑term weakness. The RSI of 49 is neutral, while a bearish MACD histogram signals downward momentum. Nonetheless, the stock remains above the identified support at ¥3,300 and below the 52‑week high of ¥3,705, giving room for upside. Volatility over the past 30 days is elevated at 27%, yet beta is low at 0.29, indicating limited systematic risk. The “Greed” reading on the fear‑greed index (72.5) points to bullish sentiment among investors. Overall, the blend of strong fundamentals and modest technical headwinds supports a cautious but optimistic outlook.
Technically, the price sits above the 50‑day SMA (¥3,254) but below the 20‑day SMA (¥3,520), reflecting short‑term weakness. The RSI of 49 is neutral, while a bearish MACD histogram signals downward momentum. Nonetheless, the stock remains above the identified support at ¥3,300 and below the 52‑week high of ¥3,705, giving room for upside. Volatility over the past 30 days is elevated at 27%, yet beta is low at 0.29, indicating limited systematic risk. The “Greed” reading on the fear‑greed index (72.5) points to bullish sentiment among investors. Overall, the blend of strong fundamentals and modest technical headwinds supports a cautious but optimistic outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Strong earnings growth but short‑term technical weakness
- Current price modestly above DCF fair value
- Stable dividend supports income focus
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Robust margins and cash‑rich balance sheet
- Valuation advantage versus industry peers
- Sustainable dividend adds total return potential
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Durable pharma pipeline and demographic tailwinds in healthcare
- Low systematic risk (beta 0.29) and strong cash position
- Consistent profitability and dividend growth prospects
Key Metrics & Analysis
Financial Health
Revenue Growth23.50%
Profit Margin41.86%
P/E Ratio16.9
ROE13.51%
ROA6.84%
Debt/Equity1.50
P/B Ratio1.9
Op. Cash Flow¥199.4B
Industry P/E26.3
Technical Analysis
TrendBullish
RSI49.1
Support¥3,300.00
Resistance¥3,705.00
MA 20¥3,520.05
MA 50¥3,254.43
MA 200¥2,741.39
MACDBearish
VolumeStable
Fear & Greed Index72.45
Valuation
Fair Value¥6,064.01
Target Price¥3,218.00
Upside/Downside-5.60%
GradeFair
TypeBlend
Dividend Yield1.94%
Risk Assessment
Beta0.29
Volatility27.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.